Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
Sept. 21 — The Food and Drug Administration said Sept. 21 it's investigating the use of the pain medicine tramadol in children aged 17 years and younger because of the rare but serious risk of slowed or difficult breathing.
The agency said in an online posting that the risk may be increased in children treated with tramadol for pain after surgery to remove their tonsils and/or adenoids. “We are evaluating all available information and will communicate our final conclusions and recommendations to the public when our review is complete.”
The FDA explained that tramadol is a specific type of narcotic medicine called an opioid that is approved to treat moderate to moderately severe pain in adults. The drug is available under the brand names Ultram, Ultram ER and Conzip, and also as a generic. Tramadol is also available in combination with the pain reliever acetaminophen under the brand name Ultracet and in generic form, the FDA said.
The agency added that tramadol is not FDA-approved for use in children. However, the FDA said data show it's being used “off-label” in the pediatric population.
Health-care professionals should be aware of this and consider prescribing alternative FDA-approved pain medicines for children, the agency said. Parents and caregivers of children taking tramadol who notice any signs of slow or shallow breathing, difficult or noisy breathing, confusion, or unusual sleepiness should stop tramadol and seek medical attention immediately by taking their child to the emergency room or calling 911.
The FDA said treating pain in children “is important because it can lead to faster recoveries and fewer complications. Untreated pain can potentially result in long-term physical and psychological consequences. There are other pain medicines available that do not have this side effect of slowed or difficult breathing associated with tramadol and are FDA-approved for use in children.”
In the body, tramadol is converted in the liver to the active form of the opioid, called O-desmethyltramadol, the agency said. “Some people have genetic variations that cause tramadol to be converted to the active form of the opioid faster and more completely than usual,” the FDA said, adding that these people, called ultra-rapid metabolizers, “are more likely to have higher-than-normal amounts of the active form of the opioid in their blood after taking tramadol, which can result in breathing difficulty that may lead to death.”
Recently, a five-year-old child in France experienced severely slowed and difficult breathing requiring emergency intervention and hospitalization after taking a single prescribed dose of tramadol oral solution for pain relief following surgery to remove his tonsils and adenoids, the agency said. The child was later found to be an ultra-rapid metabolizer and had high levels of O-desmethyltramadol in his body.
More information is available at http://tinyurl.com/nhewvum.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)